MedTrace Logo

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

NCT00532194 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2015-09-23

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum based treatment.

Conditions

Interventions

DRUG

cediranib

Once-daily oral tablet starting dose 20mg

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Australia New Zealand Gynaecological Oncology Group

    collaborator OTHER

  • NCIC Clinical Trials Group

    collaborator NETWORK

  • Grupo Español de Investigación en Cáncer de Ovario

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Medical Research Council

    lead OTHER_GOV

Principal Investigators

  • Jonathan Ledermann, Prof. · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2013-04-30
Completion
2016-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532194 on ClinicalTrials.gov